F255 Reduction in Concomitant Neuropathic Pain (Np) Medication Use After Treatment With the Capsaicin 8% Patch: A Retrospective Analysis

Wagner, Till; Roth-Daniek, Andrea; Poole, Chris

doi:10.1016/s1754-3207(11)70480-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the authors have treated patients who were able to reduce their concomitant medications following treatment with the capsaicin patch. At the clinic in Aachen, patients treated with the capsaicin 8% patch have exhibited a 54% reduction in the mean number of concomitant medications after treatment compared with baseline [29]. It is important to note, however, that concomitant medications should only be reduced following consultation between the patient and their prescribing HCP.…”

Section: Reducing Concomitant Np Medications and Patient Follow-upmentioning

confidence: 99%

Capsaicin 8% Patch for Peripheral Neuropathic Pain: Review of Treatment Best Practice from ‘Real-World‘ Clinical Experience

Wagner¹,

Roth-Daniek²,

Sell

et al. 2012

Pain Manage.

View full text Add to dashboard Cite

SUMMARY The capsaicin 8% patch is licensed in Europe for the treatment of peripheral neuropathic pain in nondiabetic adults. In controlled trials it provided pain relief for up to 3 months with a single 30- or 60-min application. In this article, a group of pain specialists from Germany and the UK share their considerable experience of real-world use of the capsaicin 8% patch. This experience comes from treating >200 patients with a variety of neuropathic pain etiologies including postherpetic neuralgia, peripheral neuropathy and cancer-related neuropathy. These patients, a slight majority of whom were female, had experienced neuropathic pain for varied lengths of time (3 months to >15 years) and the majority were receiving concomitant medications for their pain at the time of capsaicin 8% patch treatment. Observations by the group suggest that patients with positive symptoms might respond best to therapy. To optimize response to treatment, the group reports that it is important to achieve good adhesion of the patch to the skin. The experience of the group is that the capsaicin 8% patch is a tolerable treatment and local anesthetic pretreatment may not always be required. Cooling measures used after treatments were found to be the most practical and beneficial means of relieving any treatment-related discomfort. The group observed that transient, clinically important increases in blood pressure owing to treatment-related discomfort are very rare and they have seen no correlation between treatment-related discomfort or erythema and response to treatment. In the real-life clinical setting, response to capsaicin 8% patch treatment may be higher than observed in the clinical trial program. Response to retreatment also appears to be equal to that of the first treatment, even in patients treated for the fifth time. It was also observed that patients receiving capsaicin 8% patch treatment are often able to reduce their intake of concomitant pain medications. Observations from real-life use of the capsaicin 8% patch will help to maximize its therapeutic potential.

show abstract

Section: Reducing Concomitant Np Medications and Patient Follow-upmentioning

confidence: 99%

Capsaicin 8% Patch for Peripheral Neuropathic Pain: Review of Treatment Best Practice from ‘Real-World‘ Clinical Experience

Wagner¹,

Roth-Daniek²,

Sell

et al. 2012

Pain Manage.

View full text Add to dashboard Cite

show abstract

F255 Reduction in Concomitant Neuropathic Pain (Np) Medication Use After Treatment With the Capsaicin 8% Patch: A Retrospective Analysis

Cited by 1 publication

References 0 publications

Capsaicin 8% Patch for Peripheral Neuropathic Pain: Review of Treatment Best Practice from ‘Real-World‘ Clinical Experience

Capsaicin 8% Patch for Peripheral Neuropathic Pain: Review of Treatment Best Practice from ‘Real-World‘ Clinical Experience

Contact Info

Product

Resources

About